There are currently two neurotransmitter-targeting drug classes approved to treat AD: cholinesterase inhibitors and a single NMDA (N-methyl-D-aspartate) antagonist (Breijyeh and Karaman, 2020). The gene discussed is BCHE; the disease is Alzheimer disease.